MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer

"MPO-ANCA positive glomerulonephritis during PD-1 inhibitor combined with anti-CTLA4 antibody in lung cancer." Journal of Chemotherapy, 36(1), pp. 82–83

Acknowledgments

We would like to thank Editage (www.editage.com) for English language editing.

Data availability statement

The data that support the findings of this study are available from the corresponding author, [K.K], upon reasonable request.

Disclosure statement

KK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Boehringer Ingelheim, Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan, and AstraZeneca. HK has received research grants and a speaker honorarium from Ono Pharmaceutical Company, Bristol-Myers Company, Boehringer Ingelheim, MSD, Daiichi Sankyo Company, Chugai Pharmaceutical, Taiho Pharmaceutical, Merck Biopharma Company, Eli Lilly Japan, and AstraZeneca.